DBV Technologies: Bryan Garnier raises target price.
(CercleFinance.com) - Bryan Garnier reiterates its "buy" recommendation on the DBV Technologies stock and has raised its fair value from 100 euros to 105 euros, which gives the stock upside potential of 60% relative to its current price.
The broker considers that DBV Technologies is at a turning point with the reading of the Phase III trial for its major product, Viaskin Peanut, over the next few months, a trial which it believes has been "significantly derisked".
“We expect positive results to trigger a significant re-rating of the stock,” Bryan Garnier said, pointing to the transition from the business model to an "integrated biopharma" over the next 18 months.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The broker considers that DBV Technologies is at a turning point with the reading of the Phase III trial for its major product, Viaskin Peanut, over the next few months, a trial which it believes has been "significantly derisked".
“We expect positive results to trigger a significant re-rating of the stock,” Bryan Garnier said, pointing to the transition from the business model to an "integrated biopharma" over the next 18 months.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.